Drug Type Affibody, Diagnostic radiopharmaceuticals |
Synonyms luorine18 GE 226, 18FFBAZHER22891, GE 226 + [1] |
Target |
Action antagonists |
Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseClinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally advanced breast cancer | Clinical | United Kingdom | 08 Mar 2019 | |
Breast Cancer | Preclinical | United Kingdom | 15 Apr 2012 |
Not Applicable | Breast Cancer HER2 Positive | 20 | (HER2 positive) | cvgvtvpgyv(wqhkjiicgw): P-Value = <0.001 View more | Positive | 02 Jun 2022 | |
(HER2 negative) |